Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1977 1
1979 1
1980 1
1983 1
1984 4
1985 4
1987 1
1988 2
1989 2
1990 3
1992 1
1993 2
1994 2
1995 1
1996 1
1997 1
1998 1
1999 1
2000 3
2001 2
2003 2
2004 2
2006 3
2007 3
2008 1
2009 2
2010 4
2012 3
2013 6
2014 6
2015 1
2016 4
2017 1
2018 4
2019 6
2020 8
2021 7
2022 3
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

98 results

Results by year

Filters applied: . Clear all
Page 1
Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
Koh WJ, Abu-Rustum NR, Bean S, Bradley K, Campos SM, Cho KR, Chon HS, Chu C, Clark R, Cohn D, Crispens MA, Damast S, Dorigo O, Eifel PJ, Fisher CM, Frederick P, Gaffney DK, Han E, Huh WK, Lurain JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Tillmanns T, Ueda S, Wyse E, Yashar CM, McMillian NR, Scavone JL. Koh WJ, et al. J Natl Compr Canc Netw. 2019 Jan;17(1):64-84. doi: 10.6004/jnccn.2019.0001. J Natl Compr Canc Netw. 2019. PMID: 30659131
Cervical cancer is a malignant epithelial tumor that forms in the uterine cervix. Most cases of cervical cancer are preventable through human papilloma virus (HPV) vaccination, routine screening, and treatment of precancerous lesions. ...This manuscript discu …
Cervical cancer is a malignant epithelial tumor that forms in the uterine cervix. Most cases of cervical cancer are pre …
FIGO staging for carcinoma of the vulva, cervix, and corpus uteri.
FIGO Committee on Gynecologic Oncology. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet. 2014 May;125(2):97-8. doi: 10.1016/j.ijgo.2014.02.003. Epub 2014 Feb 22. Int J Gynaecol Obstet. 2014. PMID: 24630859 No abstract available.
Point-A vs. volume-based brachytherapy for the treatment of cervix cancer: A meta-analysis.
Hande V, Chopra S, Kalra B, Abdel-Wahab M, Kannan S, Tanderup K, Grover S, Zubizarreta E, Rubio JAP. Hande V, et al. Radiother Oncol. 2022 May;170:70-78. doi: 10.1016/j.radonc.2022.02.038. Epub 2022 Mar 5. Radiother Oncol. 2022. PMID: 35259419 Free PMC article.
Studies including stage I-IVA cervical cancer patients were included if standard treatment of concomitant chemo-radiotherapy and high-dose- or pulsed dose rate BT was delivered. The primary outcome was 3-year DFS, and secondary outcomes were 3-year local control (LC), 3-ye …
Studies including stage I-IVA cervical cancer patients were included if standard treatment of concomitant chemo-radiotherapy and high-dose- …
Chemotherapy and targeted therapy in the management of cervical cancer.
Kumar L, Harish P, Malik PS, Khurana S. Kumar L, et al. Curr Probl Cancer. 2018 Mar-Apr;42(2):120-128. doi: 10.1016/j.currproblcancer.2018.01.016. Epub 2018 Feb 3. Curr Probl Cancer. 2018. PMID: 29530393 Review.
Treatment with bevacizumab (an inhibitor of vascular endothelial growth factor) along with chemotherapy is associated with improved survival in patients with recurrent or metastatic cervical cancer. Weekly paclitaxel and carboplatin for 4-6 weeks as dose dense chemotherapy …
Treatment with bevacizumab (an inhibitor of vascular endothelial growth factor) along with chemotherapy is associated with improved survival …
Chemotherapy and immune check point inhibitors in the management of cervical cancer.
Kumar L, Upadhyay A, Jayaraj AS. Kumar L, et al. Curr Probl Cancer. 2022 Dec;46(6):100900. doi: 10.1016/j.currproblcancer.2022.100900. Epub 2022 Oct 11. Curr Probl Cancer. 2022. PMID: 36265252 Review.
Management of locally advanced cervix cancer underwent major change 2 decades back when concurrent chemotherapy (CCRT) (with cisplatin alone or in combination) along with definite radiation therapy (external + brachytherapy) was found to be superior compared to radi …
Management of locally advanced cervix cancer underwent major change 2 decades back when concurrent chemotherapy (CCRT) (with cisplati …
Integrating Chemotherapy in the Management of Cervical Cancer: A Critical Appraisal.
Kumar L, Gupta S. Kumar L, et al. Oncology. 2016;91 Suppl 1:8-17. doi: 10.1159/000447576. Epub 2016 Jul 28. Oncology. 2016. PMID: 27464068 Free article. Review.
The management of locally advanced cervix cancer has undergone a paradigm shift during the last decade. ...Recently, a number of molecular pathways have been identified as potential therapeutic targets. Bevacizumab - an inhibitor of vascular endothelial growth facto …
The management of locally advanced cervix cancer has undergone a paradigm shift during the last decade. ...Recently, a number of mole …
Developments in the systemic treatment of metastatic cervical cancer.
Mountzios G, Soultati A, Pectasides D, Pectasides E, Dimopoulos MA, Papadimitriou CA. Mountzios G, et al. Cancer Treat Rev. 2013 Aug;39(5):430-43. doi: 10.1016/j.ctrv.2012.05.009. Epub 2012 Jun 22. Cancer Treat Rev. 2013. PMID: 22727690 Review.
Despite the available prevention and early detection strategies, advanced squamous-cell carcinoma of the uterine cervix remains a major concern for public health. Systemic treatment with cisplatin, either in combination with external beam irradiation for locally adv …
Despite the available prevention and early detection strategies, advanced squamous-cell carcinoma of the uterine cervix remain …
Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer.
Dyer BA, Zamarin D, Eskandar RN, Mayadev JM. Dyer BA, et al. J Natl Compr Canc Netw. 2019 Jan;17(1):91-97. doi: 10.6004/jnccn.2018.7108. J Natl Compr Canc Netw. 2019. PMID: 30659133 Review.
Despite combined therapeutic approaches, there is an unmet clinical need to identify effective strategies for improved patient outcomes in treating locally advanced and metastatic cervical cancer (CC). Immunotherapy is emerging as a novel therapeutic approach …
Despite combined therapeutic approaches, there is an unmet clinical need to identify effective strategies for improved patient outcom …
The spectrum of cervical glandular neoplasia and issues in differential diagnosis.
Loureiro J, Oliva E. Loureiro J, et al. Arch Pathol Lab Med. 2014 Apr;138(4):453-83. doi: 10.5858/arpa.2012-0493-RA. Arch Pathol Lab Med. 2014. PMID: 24678677 Free article. Review.
CONTEXT: Premalignant and malignant glandular lesions of the cervix are known to often cause diagnostic problems with a variety of benign (more common) as well as other malignant mimics, the latter setting often being represented by secondary involveme …
CONTEXT: Premalignant and malignant glandular lesions of the cervix are known to often cause diagnostic problems with a variet …
EUROGIN 2011 roadmap on prevention and treatment of HPV-related disease.
Arbyn M, de Sanjosé S, Saraiya M, Sideri M, Palefsky J, Lacey C, Gillison M, Bruni L, Ronco G, Wentzensen N, Brotherton J, Qiao YL, Denny L, Bornstein J, Abramowitz L, Giuliano A, Tommasino M, Monsonego J. Arbyn M, et al. Int J Cancer. 2012 Nov 1;131(9):1969-82. doi: 10.1002/ijc.27650. Epub 2012 Jul 2. Int J Cancer. 2012. PMID: 22623137 Free PMC article. Review.
The EUROGIN 2011 roadmap reviews the current burden of human papillomavirus (HPV)-related morbidity, as well as the evidence and potential practice recommendations regarding primary and secondary prevention and treatment of cancers and other disease associated with HPV inf …
The EUROGIN 2011 roadmap reviews the current burden of human papillomavirus (HPV)-related morbidity, as well as the evidence and potential p …
98 results